- Home
- QURE vs URGN Comparison
QURE vs URGN Comparison
Compare QURE & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- URGN
- Stock Information
- Founded
- QURE 1998
- URGN 2004
- Country
- QURE Netherlands
- URGN United States
- Employees
- QURE N/A
- URGN N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- URGN Health Care
- Exchange
- QURE Nasdaq
- URGN Nasdaq
- Market Cap
- QURE 725.4M
- URGN 648.7M
- IPO Year
- QURE 2007
- URGN 2017
- Fundamental
- Price
- QURE $15.21
- URGN $18.00
- Analyst Decision
- QURE Strong Buy
- URGN Strong Buy
- Analyst Count
- QURE 10
- URGN 8
- Target Price
- QURE $37.20
- URGN $29.00
- AVG Volume (30 Days)
- QURE 1.0M
- URGN 1.5M
- Earning Date
- QURE 07-29-2025
- URGN 08-12-2025
- Dividend Yield
- QURE N/A
- URGN N/A
- EPS Growth
- QURE N/A
- URGN N/A
- EPS
- QURE N/A
- URGN N/A
- Revenue
- QURE $20,201,000.00
- URGN $91,871,000.00
- Revenue This Year
- QURE N/A
- URGN $39.80
- Revenue Next Year
- QURE $278.91
- URGN $108.94
- P/E Ratio
- QURE N/A
- URGN N/A
- Revenue Growth
- QURE 6.30
- URGN 8.98
- 52 Week Low
- QURE $4.45
- URGN $3.42
- 52 Week High
- QURE $19.18
- URGN $19.15
- Technical
- Relative Strength Index (RSI)
- QURE 55.32
- URGN 73.01
- Support Level
- QURE $13.61
- URGN $13.79
- Resistance Level
- QURE $15.49
- URGN $19.15
- Average True Range (ATR)
- QURE 0.81
- URGN 1.00
- MACD
- QURE 0.08
- URGN 0.24
- Stochastic Oscillator
- QURE 72.65
- URGN 80.48
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.